Literature DB >> 27267694

Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.

Kento Umino1, Shin-Ichiro Fujiwara1, Shoko Ito1, Kiyomi Mashima1, Daisuke Minakata1, Hirofumi Nakano1, Ryoko Yamasaki1, Yasufumi Kawasaki1, Miyuki Sugimoto1, Masahiro Ashizawa1, Kaoru Hatano1, Kiyoshi Okazuka1, Kazuya Sato1, Iekuni Oh1, Ken Ohmine1, Takahiro Suzuki1, Kazuo Muroi1, Yoshinobu Kanda1.   

Abstract

We evaluated 121 patients with follicular lymphoma (FL) and analyzed the association between the soluble interleukin-2 receptor (sIL-2R) level at diagnosis and the cumulative incidence of transformation. By a receiver-operating characteristic analysis, we determined a cutoff value of sIL-2R for transformation at 4360 U/mL to classify patients into two groups. Patients in the high sIL-2R group showed a shorter progression-free survival (PFS) and shorter disease-specific survival (DSS) (p < 0.001 and p = 0.018). Furthermore, the cumulative incidence of transformation in the high sIL-2R group was higher than that in the low sIL-2R group (40.9% vs. 7.3% at 5 years, p < 0.001). In a multivariate analysis, high sIL-2R was an independent predictive risk factor for transformation (HR 7.42, 95% CI: 2.75-20.0, p < 0.001). This study showed that the sIL-2R level at diagnosis may be a prognostic factor for transformation, PFS, and DSS in patients with FL.

Entities:  

Keywords:  Follicular lymphoma; soluble interleukin-2 receptor; transformation

Mesh:

Substances:

Year:  2016        PMID: 27267694     DOI: 10.1080/10428194.2016.1190975

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

Review 1.  Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.

Authors:  Fenghua Gao; Tingting Zhang; Hengqi Liu; Wei Li; Xianming Liu; Lihua Qiu; Lanfang Li; Shiyong Zhou; Zhengzi Qian; Sitong Dong; Sai Zhao; Xianhuo Wang; Huilai Zhang
Journal:  Ann Hematol       Date:  2022-08-27       Impact factor: 4.030

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.